Go or no go? Abbvie, Glaxo and Heron await FDA verdicts
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
US opioid crisis package nears enactment
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
